“Explore the unique challenges of evaluating immunotherapy responses with RECIST v1.1 and discover emerging criteria like irRC and iRECIST designed for more accurate assessments. Learn how these advancements are guiding effective treatment decisions in the era of immunotherapy.”

Let’s discuss the FDA's new approach to including diverse patient populations in oncology clinical trials. It emphasizes the importance of diversity in research for developing effective cancer treatments, addressing health disparities, and advancing personalized medicine. The document highlights challenges such as overcoming mistrust and logistical barriers in underrepresented communities and underscores the FDA's commitment to healthcare equity.